Clinical Trials Logo

Filter by:
NCT ID: NCT05677243 Recruiting - Clinical trials for Trigeminal Neuralgia

Observational Study on the Treatment of Trigeminal Neuralgia by Radiosurgery

NATURE
Start date: December 15, 2021
Phase:
Study type: Observational [Patient Registry]

This study aims to evaluate the outcome of patient treated by radiosurgery on LINAC with high dose rate for classical trigeminal neuralgia

NCT ID: NCT05567861 Recruiting - Fibromyalgia Clinical Trials

Virtual Reality for Fibromyalgia

VR_Fibro
Start date: October 11, 2022
Phase:
Study type: Observational

Fibromyalgia is a frequent chronic pain syndrome almost often affecting women and associating diffuse chronic musculoskeletal pain (for more than 3 months), fatigue and sleep disturbances. Other varied functional symptoms are associated with it, in particular cognitive disorders and a feeling of unrested awakening. Technological advances in virtual reality have led to recognition by the medical community as a way to improve pain and quality of life for patients. There is a growing body of evidence supporting the use of virtual reality as an adjunct therapy to reduce acute pain in patients during medical procedures in hospital settings. There may also be a role for virtual reality in patients with chronic pain.

NCT ID: NCT05553054 Recruiting - Drug Use Clinical Trials

Drug Wastage : Observational Study in Intensive Care Units in France

GAME-OVER
Start date: November 8, 2022
Phase:
Study type: Observational

Environmental awareness leads medical field to question its responsibility and possibilities for action. Drug residues can have a major environmental impact as per their bioaccumulation, toxicity and persistence characteristics, depending on where they are discarded. In France, drug residues should be disposed of by incineration, but in practice, this is not systematic. Moreover, data on drug wastage in Intensive Care Units (ICU) are rare. GAME-OVER observational study aims to evaluate drug wastage in ICU in France and to suggest ways to improve health care practices.

NCT ID: NCT05385601 Completed - Healthy Clinical Trials

Eye Movements Recording Using a Smartphone: Comparison to Standard Video-oculography and Correlation to Imaging Data in Young Athletes

Start date: May 17, 2022
Phase:
Study type: Observational

This study aims to compare measurements obtained through the e-VOG application (mobile application, usable on smartphones or tablets, to record eye movements) with measurements from the standard video-oculography device (Eye-Tracker®T2), in young athletes. This study also aims to correlate these measurements with volumetric data from cerebral imaging (if MRI done in routine care at the same period, more or less 1 month).

NCT ID: NCT05284357 Recruiting - Shoulder Fractures Clinical Trials

Post Market Clinical Follow-up Study for Arthroplasty Shoulder System of FX Solutions at the Long Term

Start date: April 7, 2022
Phase:
Study type: Observational

This study takes place in the framework of the Post-Market Clinical Follow-up of the FX Solutions Shoulder System. The goal of this PMCF study is to collect clinical data in order to confirm the safety and the performance at a long term and mainly the first two years of sales for each studied ranges. Eligible patients who received the FX Solutions Shoulder System and are at about 7 years post-operative were contacted by the Investigator to explain the study, the retrospective collection and the prospective follow-up visit. Investigator also explain the analysis of the post-operative outcomes of the patient. During the call of the investigator, the patient was informed about the study's goal and about the data collection. The oral agreement of the patient was checked by the investigators in CRF with its signature. Then, an information form explaining the purpose of the data collection was provided to the patient by postmail. The retrospective data were collected in a paper CRF via the medical file of patient. Post-operative follow-up for all patients is limited to a teleconsultation intended to assess the patient's current condition and clinical outcomes. Patient who are enrolled in the study shall be assigned a unique Subject Identification Number to de-identify their information.

NCT ID: NCT05267028 Recruiting - Family Caregivers Clinical Trials

Rehabilitation of Facial Emotion Recognition in Alzheimer's Disease

Start date: February 10, 2022
Phase:
Study type: Observational

EYE-TAR(AD+) is an observational study based on the same design as the princeps EYE-TAR(MA) study, but with a larger number of patients and including an additional evaluation of Facial emotion recognition (based on a more ecological material), in order to reinforce conclusions of the study EYE-TAR(MA) https://doi.org/10.1016/j.npg.2020.08.003. The main objective is to confirm that facial emotion recognition can be improved in AD using the "Training of Affect Recognition program" (TAR). The Secondary Objectives are to: Evaluate the impact of the "Training of Affect Recognition program" (TAR) on oculomotor behavior in a situation of social cognition, on behavioral disorders and on caregiver burden. Confirm that improvement in facial emotion recognition is related to modification of observation strategies. Confirm the link between improved recognition of facial emotions, reduced behavioral disorders and caregiver burden.

NCT ID: NCT05254873 Completed - Family Caregivers Clinical Trials

Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study.

Start date: February 5, 2022
Phase:
Study type: Observational

EYE-TAR(MA)-Follow-Up is a non-interventionel, long-term follow-up study in subjects who participated to the study referred as EYE-TAR(MA) (NCT04730440) EYE-TAR(MA)-Follow-Up aims to evaluate the long-term impacts of the Training of Affect Recognition TAR (an emotion recognition rehabilitation program), on social cognition abilities, evolve gaze strategies, behavioral disorders, and the caregiver's burden in Alzheimer's disease (AD). Subjects who completed EYE-TAR(MA) study, and who have signed informed consent for this follow-up, will be eligible to enroll. They will attend one visit two years post EYE-TAR(MA) study intervention (intervention was TAR, or a "classic" cognitive stimulation program) to undergo the following evaluation: Eye-tracking recording during Ekman Faces task, Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Zarit scale (completed by caregiver).

NCT ID: NCT05211752 Completed - Healthy Clinical Trials

Eye Movements Recording Using a Mobile : Comparison to Standard Video-oculography in Young Athletes

e-VOG(YA)
Start date: January 18, 2022
Phase:
Study type: Observational

This study aims to compare measurements obtained through the e-VOG application (mobile application, usable on smartphones or tablets, to measure eye movements) with measurements from the standard video-oculography device (Eye-Tracker®T2), in young athletes.

NCT ID: NCT05085873 Recruiting - Palliative Care Clinical Trials

Sodium Oxybate Versus Midazolam for Comfort Sedation

ONAMI
Start date: October 14, 2021
Phase: Phase 4
Study type: Interventional

The study aims at deepen the proof level of sodium oxybate use for comfort sedation at the end of life in a palliative care unit by comparing it to midazolam in a prospective randomized study with blinded efficacy evaluation. The study will be carried out for a period of 24 months with a recruitment objective of 22 patients with refractory suffering and with a short-term prognosis.

NCT ID: NCT05084950 Recruiting - COVID-19 Clinical Trials

Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)

MonaVacc
Start date: July 1, 2021
Phase:
Study type: Observational

Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.